Response Oncology Stock Revenue
Response Oncology fundamentals help investors to digest information that contributes to Response Oncology's financial success or failures. It also enables traders to predict the movement of Response Stock. The fundamental analysis module provides a way to measure Response Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Response Oncology stock.
Response |
Response Oncology Company Revenue Analysis
Response Oncology's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Response Oncology Revenue | 118.08 M |
Most of Response Oncology's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Response Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Response Oncology reported 118.08 M of revenue. This is much higher than that of the Health Care Providers & Services sector and significantly higher than that of the Health Care industry. The revenue for all United States stocks is notably lower than that of the firm.
Response Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Response Oncology's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Response Oncology could also be used in its relative valuation, which is a method of valuing Response Oncology by comparing valuation metrics of similar companies.Response Oncology is currently under evaluation in revenue category among its peers.
Response Fundamentals
| Return On Equity | -7.24 | |||
| Return On Asset | -0.0153 | |||
| Profit Margin | (0.47) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 16.62 M | |||
| Shares Outstanding | 12.18 M | |||
| Revenue | 118.08 M | |||
| Gross Profit | 28.17 M | |||
| EBITDA | 1.32 M | |||
| Net Income | (51.39 M) | |||
| Cash And Equivalents | 9.01 M | |||
| Cash Per Share | 0.74 X | |||
| Total Debt | 26.45 M | |||
| Current Ratio | 13.35 X | |||
| Book Value Per Share | (1.54) X | |||
| Cash Flow From Operations | 9.1 M | |||
| Earnings Per Share | (4.16) X | |||
| Number Of Employees | 10 | |||
| Beta | -19.24 | |||
| Market Capitalization | 12 | |||
| Total Asset | 28.9 M | |||
| Retained Earnings | (120.16 M) | |||
| Working Capital | 34.72 M | |||
| Current Asset | 37.25 M | |||
| Current Liabilities | 2.54 M | |||
| Z Score | -0.15 | |||
| Net Asset | 28.9 M |
About Response Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Response Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Response Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Response Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Response Stock
If you are still planning to invest in Response Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Response Oncology's history and understand the potential risks before investing.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |